PTCL Clinical Trials

17 clinical trials for PTCL across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL — RECRUITING · PHASE1
• Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL — RECRUITING · PHASE2
• A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. — RECRUITING
• A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma — NOT_YET_RECRUITING · PHASE1
• SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) — NOT_YET_RECRUITING · PHASE1
• A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma. — NOT_YET_RECRUITING
• TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma — NOT_YET_RECRUITING · PHASE3
• Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL — ACTIVE_NOT_RECRUITING · PHASE1
• Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL — NOT_YET_RECRUITING · PHASE1
• SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort — COMPLETED · PHASE1
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms — COMPLETED · PHASE2
• Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma — OTHER · PHASE2
• Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL — OTHER · PHASE1
• A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma — OTHER · PHASE2
• GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL — OTHER
• Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL — WITHDRAWN · PHASE1

Refine this search